Document Detail


A patient's point of view.
MedLine Citation:
PMID:  21504294     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Patients have many concerns when diagnosed with hairy cell leukemia (HCL). Their ultimate concern is whether they will be cured. Although purine nucleoside analogs have been very effective in the treatment of HCL, some patients do not respond to these therapies and many relapse after initial treatment. From a patient's point of view, it is gratifying to know that researchers continue their efforts to develop more effective treatments with minimal side effects. By forming the Hairy Cell Leukemia Consortium, these researchers seek to educate patients and doctors around the world and continue their quest for a cure for hairy cell leukemia.
Authors:
Earl J Stone
Related Documents :
23246614 - The iso/iec 11179 norm for metadata registries: does it cover healthcare standards in e...
7801164 - Drugs, sex and social science: social science research and health policy in australia.
8010324 - Development of a successful research grant application.
24503494 - Psychological aspects of hand transplantation.
24865634 - Rolf bernander (1956-2014): pioneer of the archaeal cell cycle.
18840244 - Mustard gas and american race-based human experimentation in world war ii.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-4-19
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  -     ISSN:  1029-2403     ISO Abbreviation:  -     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-4-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Hairy Cell Leukemia Research Foundation, Inc, Deerfield, IL, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Development of cladribine at Scripps for hairy cell leukemia and current results.
Next Document:  Molecular analysis of WT1 and KIT mutations in patients from an Indian population with de novo acute...